StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Elite Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $34.94M, down 6.7% year over year. For fiscal 2026 it was $49.11M, up 150.6% from the year before. The highest annual figure on record is $49.11M in fiscal 2026.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026$49.11M+150.6%
FY2025Mar 31, 2025$19.60M+81.7%
FY2024Mar 31, 2024$10.79M+193.5%
FY2023Mar 31, 2023$3.68M-27.5%
FY2022Mar 31, 2022$5.07M+140.9%
FY2021Mar 31, 2021$2.10M–
FY2020Mar 31, 2020-$2.29M–
FY2019Mar 31, 2019-$9.16M–
FY2018Mar 31, 2018-$9.05M–
FY2017Mar 31, 2017-$7.36M–
FY2016Mar 31, 2016-$8.32M–
FY2015Mar 31, 2015-$16.51M–
FY2014Mar 31, 2014-$5.28M–
FY2013Mar 31, 2013-$1.56M–
FY2012Mar 31, 2012-$1.97M–
FY2011Mar 31, 2011-$885.76K–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$7.53M-65.3%
Q4 FY2026CQ1 2026Mar 31, 2026$10.19M-8.7%
Q3 FY2026CQ4 2025Dec 31, 2025$9.01M+721.0%
Q2 FY2026CQ3 2025Sep 30, 2025$8.21M+135.7%
Q1 FY2026CQ2 2025Jun 30, 2025$21.70M+461.6%
Q4 FY2025CQ1 2025Mar 31, 2025$11.15M+199.1%
Q3 FY2025CQ4 2024Dec 31, 2024$1.10M-68.9%
Q2 FY2025CQ3 2024Sep 30, 2024$3.48M+81.0%
Q1 FY2025CQ2 2024Jun 30, 2024$3.86M+141.2%
Q4 FY2024CQ1 2024Mar 31, 2024$3.73M–
Q3 FY2024CQ4 2023Dec 31, 2023$3.53M+80.3%
Q2 FY2024CQ3 2023Sep 30, 2023$1.93M+78.1%
Q1 FY2024CQ2 2023Jun 30, 2023$1.60M+56.6%
Q4 FY2023CQ1 2023Mar 31, 2023-$386.90K-145.4%
Q3 FY2023CQ4 2022Dec 31, 2022$1.96M+7.0%
Q2 FY2023CQ3 2022Sep 30, 2022$1.08M-24.0%
Q1 FY2023CQ2 2022Jun 30, 2022$1.02M+6.0%
Q4 FY2022CQ1 2022Mar 31, 2022$851.68K–
Q3 FY2022CQ4 2021Dec 31, 2021$1.83M+82.9%
Q2 FY2022CQ3 2021Sep 30, 2021$1.42M+6.1%
Q1 FY2022CQ2 2021Jun 30, 2021$965.16K+16.2%
Q4 FY2021CQ1 2021Mar 31, 2021-$1.07M–
Q3 FY2021CQ4 2020Dec 31, 2020$1.00M+44.8%
Q2 FY2021CQ3 2020Sep 30, 2020$1.34M–
Q1 FY2021CQ2 2020Jun 30, 2020$830.60K–
Q4 FY2020CQ1 2020Mar 31, 2020-$1.37M–
Q3 FY2020CQ4 2019Dec 31, 2019$691.20K–
Q2 FY2020CQ3 2019Sep 30, 2019-$454.53K–
Q1 FY2020CQ2 2019Jun 30, 2019-$1.15M–
Q4 FY2019CQ1 2019Mar 31, 2019-$2.01M–
Q3 FY2019CQ4 2018Dec 31, 2018-$2.64M–
Q2 FY2019CQ3 2018Sep 30, 2018-$2.65M–
Q1 FY2019CQ2 2018Jun 30, 2018-$1.86M–
Q4 FY2018CQ1 2018Mar 31, 2018-$2.62M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.06M–
Q2 FY2018CQ3 2017Sep 30, 2017-$2.13M–
Q1 FY2018CQ2 2017Jun 30, 2017-$2.24M–
Q4 FY2017CQ1 2017Mar 31, 2017-$3.19M–
Q3 FY2017CQ4 2016Dec 31, 2016-$1.72M–
Q2 FY2017CQ3 2016Sep 30, 2016-$1.21M–

More Elite Pharmaceuticals figures

See a number that looks wrong?